リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor.」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor.

Yasushi Yabuki Jiaqi Liu Ichiro Kawahata Hisanao Izumi Yasuharu Shinoda Kohei Koga Shinya Ueno Norifumi Shioda Kohji Fukunaga 東北大学 DOI:10.3390/ijms21155525

2020.08.01

概要

Recently, we developed the fatty acid-binding protein 3 (FABP3) ligand MF1 (4-(2-(1-(2-chlorophenyl)-5-phenyl-1H-pyrazol-3-yl)phenoxy) butanoic acid) as a therapeutic candidate for α-synucleinopathies. MF1 shows affinity towards γ-aminobutyric acid type-A (GABAA) receptor, but its effect on the receptor remains unclear. Here, we investigate the pharmacological properties of MF1 on the GABAA receptor overexpressed in Neuro2A cells. While MF1 (1–100 µm) alone failed to evoke GABA currents, MF1 (1 µm) promoted GABA currents during GABA exposure (1 and 10 µm). MF1-promoted GABA currents were blocked by flumazenil (10 µm) treatment, suggesting that MF1 enhances receptor function via the benzodiazepine recognition site. Acute and chronic administration of MF1 (0.1, 0.3 and 1.0 mg/kg, p.o.) significantly attenuated status epilepticus (SE) and the mortality rate in pilocarpine (PILO: 300 mg/kg, i.p.)-treated mice, similar to diazepam (DZP: 5.0 mg/kg, i.p.). The anti-epileptic effects of DZP (5.0 mg/kg, i.p.) and MF1 (0.3 mg/kg, p.o.) were completely abolished by flumazenil (25 mg/kg, i.p.) treatment. Pentylenetetrazol (PTZ: 90 mg/kg, i.p.)-induced seizures in mice were suppressed by DZP (5.0 mg/kg, i.p.), but not MF1. Collectively, this suggests that MF1 is a mild enhancer of the GABAA receptor and exercises anti-epileptic effects through the receptor’s benzodiazepine recognition site in PILO-induced SE models.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Whiting, P.J.; Bonnert, T.P.; McKernan, R.M.; Farrar, S.; Le Bourdellès, B.; Heavens, R.P.; Smith, D.W.; Hewson, L.; Rigby, M.R.; Sirinathsinghji, D.J.; et al. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann. N. Y. Acad. Sci. 1999, 868, 645–653. [CrossRef] [PubMed]

2. Mitchell, S.J.; Silver, R.A. Shunting inhibition modulates neuronal gain during synaptic excitation. Neuron2003, 38, 433–445. [CrossRef]

3. Crunelli, V.; Lo˝rincz, M.L.; McCafferty, C.; Lambert, R.C.; Leresche, N.; Di Giovanni, G.; David, F. Clinical and experimental insight into pathophysiology, comorbidity and therapy of absence seizures. Brain 2020, 21, awaa072. [CrossRef] [PubMed]

4. Rogawski, M.A.; Löscher, W.; Rho, J.M. Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.Cold Spring Harb. Perspect. Med. 2016, 6, a022780. [CrossRef] [PubMed]

5. Błaszczyk, J.W. Parkinson’s Disease and Neurodegeneration: GABA-Collapse Hypothesis. Front. Neurosci.2016, 10, 269. [CrossRef] [PubMed]

6. Bi, D.; Wen, L.; Wu, Z.; Shen, Y. GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer’s disease. Alzheimers Dement. 2020, 1–18. [CrossRef]

7. Fung, L.K.; Flores, R.E.; Gu, M.; Sun, K.L.; James, D.; Schuck, R.K.; Jo, B.; Park, J.H.; Lee, B.C.; Jung, J.H.; et al. Thalamic and prefrontal GABA concentrations but not GABA(A) receptor densities are altered in high-functioning adults with autism spectrum disorder. Mol. Psychiatry 2020. [CrossRef]

8. Faulkner, M.A.; Singh, S.P. Neurogenetic disorders and treatment of associated seizures. Pharmacotherapy 2013, 33, 330–343. [CrossRef]

9. Giorgi, F.S.; Saccaro, L.F.; Busceti, C.L.; Biagioni, F.; Fornai, F. Epilepsy and Alzheimer’s Disease: Potential mechanisms for an association. Brain Res. Bull. 2020, 160, 107–120. [CrossRef]

10. Löscher, W. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs. Neurochem. Res. 2017, 42, 1873–1888. [CrossRef]

11. Czapin´ski, P.; Blaszczyk, B.; Czuczwar, S.J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 3–14. [CrossRef] [PubMed]

12. Bormann, J. The ‘ABC’ of GABA Receptors. Trends Pharmacol. Sci. 2000, 21, 16–19. [CrossRef]

13. Rudolph, U.; Möhler, H. GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu. Rev. Pharmacol. Toxicol. 2014, 54, 483–507. [CrossRef] [PubMed]

14. Sassoè-Pognetto, M.; Fritschy, J.M. Mini-review: Gephyrin, a Major Postsynaptic Protein of GABAergic Synapses. Eur. J. Neurosci. 2000, 12, 2205–2210. [CrossRef] [PubMed]

15. Glykys, J.; Mody, I. Activation of GABAA Receptors: Views from Outside the Synaptic Cleft. Neuron 2007,56, 763–770. [CrossRef]

16. Coe, N.R.; Bernlohr, D.A. Physiological properties and functions of intracellular fatty acid-binding proteins.Biochim. Biophys. Acta 1998, 1391, 287–306. [CrossRef]

17. Owada, Y.; Yoshimoto, T.; Kondo, H. Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains. J. Chem. Neuroanat. 1996, 12, 113–122. [CrossRef]

18. Owada, Y. Fatty acid binding protein: Localization and functional significance in the brain. Tohoku J. Exp. Med. 2008, 214, 213–220. [CrossRef]

19. Sepe, F.N.; Chiasserini, D.; Parnetti, L. Role of FABP3 as biomarker in Alzheimer’s disease and synucleinopathies. Future Neurol. 2018, 13, 199–207. [CrossRef]

20. Chiasserini, D.; Biscetti, L.; Eusebi, P.; Salvadori, N.; Frattini, G.; Simoni, S.; De Roeck, N.; Tambasco, N.; Stoops, E.; Vanderstichele, H.; et al. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia. Alzheimers Res. Ther. 2017, 9, 52. [CrossRef]

21. Bjerke, M.; Kern, S.; Blennow, K.; Zetterberg, H.; Waern, M.; Börjesson-Hanson, A.; Östling, S.; Kern, J.; Skoog, I. Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. J. Alzheimers Dis. 2016, 49, 733–741. [CrossRef] [PubMed]

22. Shioda, N.; Yabuki, Y.; Kobayashi, Y.; Onozato, M.; Owada, Y.; Fukunaga, K. FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity. J. Biol. Chem. 2014, 289, 18957–18965. [CrossRef] [PubMed]

23. Yabuki, Y.; Matsuo, K.; Kawahata, I.; Fukui, N.; Mizobata, T.; Kawata, Y.; Owada, Y.; Shioda, N.; Fukunaga, K. Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain. Int. J. Mol. Sci. 2020, 21, 2230. [CrossRef] [PubMed]

24. Kawahata, I.; Bousset, L.; Melki, R.; Fukunaga, K. Fatty Acid-Binding Protein 3 is Critical for α-Synuclein Uptake and MPP+-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons. Int. J. Mol. Sci. 2019, 20, 5358. [CrossRef]

25. Cheng, A.; Shinoda, Y.; Yamamoto, T.; Miyachi, H.; Fukunaga, K. Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization. Brain Res. 2019, 1707, 190–197. [CrossRef]

26. Matsuo, K.; Cheng, A.; Yabuki, Y.; Takahata, I.; Miyachi, H.; Fukunaga, K. Inhibition of MPTP-induced α-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice. Neuropharmacology 2019, 150, 164–174. [CrossRef]

27. Liu, Y.M.; Fan, H.R.; Ding, J.; Huang, C.; Deng, S.; Zhu, T.; Xu, T.L.; Ge, W.H.; Li, W.G.; Li, F. Curcumol allosterically modulates GABA(A) receptors in a manner distinct from benzodiazepines. Sci. Rep. 2017, 7, 46654. [CrossRef]

28. Costa, J.P.; Ferreira, P.B.; De Sousa, D.P.; Jordan, J.; Freitas, R.M. Anticonvulsant effect of phytol in a pilocarpine model in mice. Neurosci. Lett. 2012, 523, 115–118. [CrossRef]

29. Khoshnoud, M.J.; Tanideh, N.; Namdarian, S. Anticonvulsant activity of atorvastatin against seizure induced by pentylenetetrazole and maximal electroshock in mice. Trends Pharm. Sci. 2015, 1, 44–47.

30. Vonderlin, N.; Fischer, F.; Zitron, E.; Seyler, C.; Scherer, D.; Thomas, D.; Katus, H.A.; Scholz, E.P. Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: Mode of action. Drug Des. Dev. Ther. 2014, 8, 2263–2271. [CrossRef]

31. So, E.C.; Wu, K.C.; Kao, F.C.; Wu, S.N. Effects of midazolam on ion currents and membrane potential in differentiated motor neuron-like NSC-34 and NG108-15 cells. Eur. J. Pharmacol. 2014, 724, 152–160. [CrossRef] [PubMed]

32. Smolders, I.; Khan, G.M.; Manil, J.; Ebinger, G.; Michotte, Y. NMDA receptor-mediated pilocarpine-induced seizures: Characterization in freely moving rats by microdialysis. Br. J. Pharmacol. 1997, 121, 1171–1179. [CrossRef] [PubMed]

33. Millan, M.H.; Chapman, A.G.; Meldrum, B.S. Extracellular amino acid levels in hippocampus during pilocarpine-induced seizures. Epilepsy Res. 1993, 14, 139–148. [CrossRef]

34. Macdonald, R.L.; Kapur, J. Acute cellular alterations in the hippocampus after status epilepticus. Epilepsia1999, 40, S9–S20. [CrossRef] [PubMed]

35. Ramanjaneyulu, R.; Ticku, M.K. Interactions of pentamethylenetetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. Eur. J. Pharmacol. 1984, 98, 337–345. [CrossRef]

36. Hansen, S.L.; Sperling, B.B.; Sánchez, C. Anticonvulsant and antiepileptogenic effects of GABAA receptor ligands in pentylenetetrazole-kindled mice. Pharmacology 1984, 98, 337–345. [CrossRef] [PubMed]

37. Rodrigues de Oliveira, F.; Eleuterio Rodrigues, K.; Hamoy, M.; Sarquis, Í.R.; Otake Hamoy, A.; Crespo Lopez, M.E.; Maciel Ferreira, I.; Macchi, B.M.; Luiz Martins do Nascimento, J. Fatty Acid Amides Synthesized from Andiroba Oil (Carapa guianensis Aublet.) Exhibit Anticonvulsant Action with Modulation on GABA-A Receptor in Mice: A Putative Therapeutic Option. Pharmaceuticals 2020, 13, 43. [CrossRef]

38. Yamamoto, Y.; Kida, H.; Kagawa, Y.; Yasumoto, Y.; Miyazaki, H.; Islam, A.; Ogata, M.; Yanagawa, Y.; Mitsushima, D.; Fukunaga, K.; et al. FABP3 in the Anterior Cingulate Cortex Modulates the Methylation Status of the Glutamic Acid Decarboxylase67 Promoter Region. J. Neurosci. 2018, 38, 10411–10423. [CrossRef]

39. Yabuki, Y.; Takahata, I.; Matsuo, K.; Owada, Y.; Fukunaga, K. Ramelteon Improves Post-traumatic Stress Disorder-Like Behaviors Exhibited by Fatty Acid-Binding Protein 3 Null Mice. Mol. Neurobiol. 2018, 55, 3577–3591. [CrossRef]

40. Riss, J.; Cloyd, J.; Gates, J.; Collins, S. Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics.Acta Neurol. Scand. 2008, 118, 69–86. [CrossRef]

41. Parsonage, M.J.; Norris, J.W. Use of diazepam in the treatment of severe convulsive status epilepticus. Br. Med. J. 1967, 3, 85–88. [CrossRef] [PubMed]

42. Beagle, A.J.; Darwish, S.M.; Ranasinghe, K.G.; La, A.L.; Karageorgiou, E.; Vossel, K.A. Relative Incidence of Seizures and Myoclonus in Alzheimer’s Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia.J. Alzheimers Dis. 2017, 60, 211–223. [CrossRef] [PubMed]

43. Murata, M.; Horiuchi, E.; Kanazawa, I. Zonisamide has beneficial effects on Parkinson’s disease patients.Neurosci. Res. 2001, 41, 397–399. [CrossRef]

44. Beniyama, Y.; Matsuno, K.; Miyachi, H. Structure-guided design, synthesis and in vitro evaluation of a series of pyrazole-based fatty acid binding protein (FABP) 3 ligands. Bioorg. Med. Chem. Lett. 2013, 23, 1662–1666. [CrossRef] [PubMed]

45. Migita, K.; Yamada, J.; Nikaido, Y.; Shi, X.; Kaneko, S.; Hirose, S.; Ueno, S. Properties of a novel GABAA receptor γ2 subunit mutation associated with seizures. J. Pharmacol. Sci. 2013, 121, 84–87. [CrossRef]

46. Yabuki, Y.; Matsuo, K.; Izumi, H.; Haga, H.; Yoshida, T.; Wakamori, M.; Kakei, A.; Sakimura, K.; Fukuda, T.; Fukunaga, K. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology 2017, 117, 1–13. [CrossRef]

47. Racine, R.J. Modification of Seizure Activity by Electrical Stimulation. II. Motor Seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32, 281–294. [CrossRef]

48. Lowenstein, D.H.; Alldredge, B.K. Status Epilepticus. N. Engl. J. Med. 1998, 338, 970–976. [CrossRef]

49. Shibley, H.; Smith, B.N. Pilocarpine-induced status epilepticus results in mossy fiber sprouting and spontaneous seizures in C57BL/6 and CD-1 mice. Epilepsy Res. 2002, 49, 109–120. [CrossRef]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る